Illumina (NASDAQ: ILMN) — Perfil da empresa, notícias e dados financeiros
Illumina advances human health through innovative sequencing technologies for genetic research in oncology and reproductive health.
Illumina
Illumina is a global life science company focused on genetic analysis through DNA sequencing and array-based technologies. The company develops, manufactures, and markets next-generation sequencing systems, microarrays, library preparation kits, sequencing reagents, and bioinformatics software solutions. Its products enable researchers and healthcare professionals to perform genetic research, molecular diagnostics, reproductive health testing, and complex disease analysis. Illumina serves customers in academic, government, pharmaceutical, biotechnology, and clinical settings worldwide, supporting applications across oncology, rare genetic diseases, agrigenomics, and microbiology.
Resumo
Operações
Produtos e/ou serviços de Illumina
- Sequencing Platforms: High-throughput and benchtop next-generation sequencing instruments designed for genetic research and clinical diagnostics. These platforms utilize sequencing-by-synthesis technology to generate comprehensive genomic, transcriptomic, and epigenomic data across varied sample throughput requirements.
- Sequencing Reagents and Consumables: Dedicated chemical kits, flow cells, and library preparation reagents used during genomic sequencing runs. These consumables drive recurring operational usage and enable sample preparation, targeted enrichment, and high-fidelity base reading for diverse sequencing applications.
- Microarray Instruments and Kits: High-density microarray scanners and assay beadchips used for large-scale genotyping, copy number variant analysis, and gene expression profiling. These systems support population genomics studies, consumer genomics, and agricultural biotechnology research.
- Bioinformatics and Informatics Software: Cloud-based and on-premise software platforms, including secondary analysis engines and clinical reporting tools, designed to process, interpret, and store high-volume genomic data efficiently for research and diagnostic workflows.
- In Vitro Diagnostic Solutions: Regulated clinical diagnostic instruments and assay kits cleared for medical applications, including noninvasive prenatal testing, hereditary cancer screening, and companion diagnostic tumor profiling in clinical laboratory environments.
- Genomic Services and Training: Specialized sequencing services, proactive instrument monitoring, laboratory setup support, and technical training programs provided to academic, pharmaceutical, and clinical institutions operating genomic infrastructure globally.
equipe executiva do Illumina
- Jacob ThaysenCEO, President & Director
- Ankur DhingraChief Financial Officer
- Kevin Carl PegelsChief of Global Operations
- Steven BarnardChief Technology Officer
- Scott EricksenVP & Chief Accounting Officer
- Mark FieldChief Information Officer
- Conor Noel McNamaraVP of Investor Relations
- Julie Ann ColettiChief Legal Officer
- Jakob WedelChief Strategy & Corporate Development Officer
- Patricia LeckmanSenior VP & Chief People Officer
Principais indicadores financeiros
Resultados divulgados pela Illumina, em USD.
- Cap. de mercado
- 43,6 bi
- Receita (TTM)
- 4,5 bi
- P/L
- 53.9
- LPA (diluído, TTM)
- 5.4
- Dividend yield
- —
- Margem de lucro
- 18.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 4,3 bi | 864 mi | 850 mi | |
| 4,4 bi | -833 mi | -1,2 bi | |
| 4,5 bi | -1,1 bi | -1,2 bi | |
| 4,6 bi | -4,2 bi | -4,4 bi |